Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4243136
Max Phase: Preclinical
Molecular Formula: C54H101N17O10
Molecular Weight: 1148.51
Molecule Type: Small molecule
Associated Items:
ID: ALA4243136
Max Phase: Preclinical
Molecular Formula: C54H101N17O10
Molecular Weight: 1148.51
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(N)=O)C(C)C
Standard InChI: InChI=1S/C54H101N17O10/c1-29(2)25-38(63-34(11)72)47(76)67-40(27-31(5)6)49(78)69-41(28-32(7)8)50(79)68-39(26-30(3)4)48(77)64-36(18-14-22-61-53(57)58)46(75)70-43(33(9)10)51(80)65-35(17-12-13-21-55)45(74)66-37(19-15-23-62-54(59)60)52(81)71-24-16-20-42(71)44(56)73/h29-33,35-43H,12-28,55H2,1-11H3,(H2,56,73)(H,63,72)(H,64,77)(H,65,80)(H,66,74)(H,67,76)(H,68,79)(H,69,78)(H,70,75)(H4,57,58,61)(H4,59,60,62)/t35-,36-,37-,38-,39-,40-,41-,42-,43-/m0/s1
Standard InChI Key: ZUSUFNALANSLQL-GMIRWQTLSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1148.51 | Molecular Weight (Monoisotopic): 1147.7917 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Dianati V, Kwiatkowska A, Couture F, Desjardins R, Dory YL, Day R.. (2018) Increasing C-Terminal Hydrophobicity Improves the Cell Permeability and Antiproliferative Activity of PACE4 Inhibitors against Prostate Cancer Cell Lines., 61 (18): [PMID:30180568] [10.1021/acs.jmedchem.8b01144] |
Source(1):